The expression of SMARCA4, which is one of the main topics in this paper, is absent in around 10% of human primary non-small-cell lung cancers (NSCLC) and its loss is associated with poor patient survival14. This evidence concerns the gene SMARCA4 and non-small cell lung carcinoma.